Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

ER headache relief: could a steroid combo beat standard painkillers?

NCT ID NCT07605065

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a combination of two drugs (dexamethasone and metoclopramide) against standard painkillers (paracetamol or NSAIDs) for treating severe primary headaches in the emergency department. 94 adults aged 18-60 with a pain score of 5 or higher will be randomly assigned to one of the two treatments. The goal is to see which approach provides faster and more effective pain relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexamethasone plus metoclopramide (given intravenously)
What this could lead to
If it works, this could offer a faster, more effective way to relieve severe headaches in the emergency room.
What could go wrong
This is a small, single-hospital trial (94 people) and may not apply to all headache types. Side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 94 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 to 60 years. * Patients presenting with primary headache diagnosed clinically. * Patients presenting within 72 hours of onset of headache. * Patients with Visual Analogue Scale (VAS) pain score ≥5. Exclusion Criteria: * Patients with secondary headache disorders. * Patients with known allergy to dexamethasone, metoclopramide, paracetamol, or NSAIDs. * Pregnant females. * Patients with hepatic impairment. * Patients with renal impairment. * Patients with peptic ulcer disease or gastrointestinal bleeding. * Patients with extrapyramidal disorders. * Patients already receiving corticosteroids within previous 48 hours.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary headache are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.